Nuveen
TRVI icon

Nuveen’s Trevi Therapeutics TRVI Stock Holding History

Nuveen’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.3M Buy
765,176
+576,994
+307% +$8.39M ﹤0.01% 1476
2026
Q1 		$2.25M Buy
188,182
+4,853
+3% +$54.3K ﹤0.01% 2236
2025
Q4 		$2.3M Hold
183,329
– – ﹤0.01% 2231
2025
Q3 		$1.68M Buy
183,329
+13,870
+8% +$104K ﹤0.01% 2369
2025
Q2 		$927K Sell
169,459
-104,161
-38% -$648K ﹤0.01% 2639
2025
Q1 		$1.72M Buy
273,620
+177,270
+184% +$846K ﹤0.01% 2392
2024
Q4 		$397K Hold
96,350
– – ﹤0.01% 3057
2024
Q3 		$322K Hold
96,350
– – ﹤0.01% 3130
2024
Q2 		$287K Buy
96,350
+21,501
+29% +$59.7K ﹤0.01% 3161
2024
Q1 		$258K Hold
74,849
– – ﹤0.01% 3128
2023
Q4 		$100K Buy
74,849
+7,914
+12% +$12K ﹤0.01% 3286
2023
Q3 		$146K Hold
66,935
– – ﹤0.01% 3084
2023
Q2 		$160K Buy
+66,935
New +$169K ﹤0.01% 3122

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Nuveen's TRVI Position: Q2 2026 in Review

Nuveen increased its Trevi Therapeutics (TRVI) stake by 307% in Q2 2026, buying an estimated $8.39M and bringing the position to 765,176 shares worth $14.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1476.

Nuveen first reported a position in TRVI in Q2 2023 and has held it in 13 quarters since. 218 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Nuveen held 765,176 shares of Trevi Therapeutics worth $14.3M as of Q2 2026.
  • Nuveen bought 576,994 Trevi Therapeutics shares in Q2 2026, an estimated $8.39M.
  • Trevi Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #1476 holding.
  • Nuveen first reported a position in Trevi Therapeutics in Q2 2023 and has held it in 13 quarters since.
  • 218 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.